Literature DB >> 15952078

Glucagon does not affect catecholamine release in primary cultures of bovine adrenal chromaffin cells.

Y Sharabi1, R Zimlichman, S Alesci, T Huynh, R Mansouri, J Chun, S Perera, K Pacak, D S Goldstein.   

Abstract

OBJECTIVE: Human pheochromocytoma tumor cells express glucagon receptors, and bolus i.v. glucagon injection rapidly increases plasma epinephrine levels, suggesting that glucagon can directly stimulate adrenomedullary secretion. In this study, we tested whether the catecholamine secretory response to glucagon was present in bovine chromaffin cells or exclusive to the tumor cells. DESIGN AND METHODS: Adrenomedullary cells were cultured in 24-well plates (10(6) cells per well). After 48-72 hours, wells were incubated for 1-20 minutes with (1) incubation medium (control), (2) catecholamine secretagogues (nicotine or potassium ion), or (3) glucagon (10(-8) to 10(-5) M). After incubation, catecholamine contents in medium and cells were assayed by high-pressure liquid chromatography with electrochemical detection. Fractional release rates of epinephrine, norepinephrine, and dopamine were calculated and compared to controls. Reverse-transcriptase PCR was performed to compare expression of mRNA of the glucagon receptor in chromaffin cells and pheochromocytoma cells.
RESULTS: Nicotine and potassium evoked time-dependent release of epinephrine, norepinephrine, and dopamine. Glucagon did not affect catecholamine secretion at any concentration. Reverse-transcriptase PCR failed to detect mRNA for glucagon receptor in bovine adrenomedullary cells, but did detect it in human pheochromocytoma cells.
CONCLUSIONS: In contrast to pheochromocytoma tumor cells, bovine adrenomedullary chromaffin cells do not express the glucagon receptor, and therefore do not secrete catecholamines in response to glucagon.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15952078     DOI: 10.1055/s-2005-861415

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  2 in total

1.  Adrenomedullary response to glucagon in patients with primary Sjögren's syndrome.

Authors:  Richard Imrich; Nikolay P Nikolov; Lolita Bebris; Ilias Alevizos; David S Goldstein; Courtney S Holmes; Gabor G Illei
Journal:  Cell Mol Neurobiol       Date:  2012-02-18       Impact factor: 5.046

2.  Generalized and neurotransmitter-selective noradrenergic denervation in Parkinson's disease with orthostatic hypotension.

Authors:  Yehonatan Sharabi; Richard Imrich; Courtney Holmes; Sandra Pechnik; David S Goldstein
Journal:  Mov Disord       Date:  2008-09-15       Impact factor: 10.338

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.